- List
- By Topic
- On Map
- Search Details

Histiocytosis, Non-Langerhans-Cell | "familial hemophagocytic lymphohistiocytosis"
Need help? See RSS Feeds
Choose a feed type:

Histiocytosis, Non-Langerhans-Cell | "familial hemophagocytic lymphohistiocytosis" (40 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT01547143 | Terminated | Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
12 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT01547143 | AMC-H-72 | HELA2012 | March 2012 | May 2016 | May 2016 | March 7, 2012 | July 20, 2018 |
|
||
2 | NCT02631109 | Recruiting | L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
120 | All | 14 Years to 75 Years (Child, Adult, Older Adult) | NCT02631109 | L-DEP-EBV-HLH | December 2015 | November 2017 | November 2019 | December 16, 2015 | August 4, 2016 |
|
|||
3 | NCT02007239 | Recruiting | Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
10 | All | 3 Months to 25 Years (Child, Adult) | NCT02007239 | 13-010459 | December 2013 | January 2021 | July 2021 | December 10, 2013 | February 7, 2019 |
|
|||
4 | NCT03259230 | Recruiting | Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) |
|
|
Observational |
|
Industry / Other |
|
|
50 | All | Child, Adult, Older Adult | NCT03259230 | NI-0501-07 PA16-0129 |
October 13, 2016 | October 2018 | October 2019 | August 23, 2017 | August 10, 2018 |
|
||||
5 | NCT01104025 | Completed | Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
31 | All | up to 18 Years (Child, Adult) | NCT01104025 | HIT-HLH | April 2010 | November 2015 | April 2016 | April 15, 2010 | November 16, 2016 |
|
|||
6 | NCT03312751 | Recruiting | Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
34 | All | up to 18 Years (Child, Adult) | NCT03312751 | NI-0501-09 | September 24, 2018 | October 2021 | October 2022 | October 18, 2017 | December 5, 2018 |
|
|||
7 | NCT01818492 | Recruiting | A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis |
|
|
Interventional |
Phase 2 Phase 3 |
|
Industry / Other |
|
|
32 | All | up to 18 Years (Child, Adult) | NCT01818492 | NI-0501-04 2012-003632-23 |
January 2013 | December 2018 | March 26, 2013 | August 27, 2018 |
|
||||
8 | NCT03117010 | Recruiting | Prospective Cohort for Adult Hemophagocytosis |
|
|
Observational |
|
Other |
|
|
81 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03117010 | 2016-08-117 | January 1, 2017 | December 31, 2020 | December 31, 2022 | April 17, 2017 | January 1, 2019 |
|
||||
9 | NCT00426101 | Completed | Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
368 | All | up to 18 Years (Child, Adult) | NCT00426101 | HLH-2004 | January 2004 | December 2011 | December 2017 | January 24, 2007 | July 4, 2018 |
|
|||
10 | NCT02912702 | Recruiting | L-DEP as an Initial Treatment for EBV-HLH |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
120 | All | 14 Years to 75 Years (Child, Adult, Older Adult) | NCT02912702 | L-DEP-EBV-HLH-First line | September 2016 | September 2018 | September 2019 | September 23, 2016 | September 23, 2016 |
|
|||
11 | NCT03795909 | Recruiting | Ruxolitinib Combined With Dexamethasone for HLH |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
50 | All | 1 Year to 18 Years (Child, Adult) | NCT03795909 | HLH-DR | March 1, 2017 | March 1, 2020 | March 1, 2022 | January 8, 2019 | January 8, 2019 |
|
|||
12 | NCT03533790 | Recruiting | DEP-Ru Regimen as a Salvage Therapy for HLH |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
80 | All | 1 Year to 70 Years (Child, Adult, Older Adult) | NCT03533790 | DEP-Ru HLH | June 2018 | June 2018 | June 2021 | May 23, 2018 | May 30, 2018 |
|
|||
13 | NCT03742115 | Not yet recruiting | Etoposide in the First-line Treatment of Adult EBV-HLH |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
90 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03742115 | VP-16-adult EBV-HLH-first line | December 1, 2018 | December 1, 2019 | December 1, 2020 | November 15, 2018 | November 15, 2018 |
|
|||
14 | NCT01818908 | Active, not recruiting | Trial of DA-EPOCH Regimen for NHL With HLH |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
50 | All | 15 Years to 80 Years (Child, Adult, Older Adult) | NCT01818908 | JSPH-HLH-001 | June 2012 | October 2018 | April 2019 | March 27, 2013 | February 15, 2019 |
|
|||
15 | NCT02069899 | Recruiting | Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody |
|
|
Interventional |
Not Applicable |
|
Industry / Other |
|
|
55 | All | Child, Adult, Older Adult | NCT02069899 | NI-0501-05 | June 2013 | September 2020 | February 24, 2014 | March 23, 2018 |
|
||||
16 | NCT00334672 | Unknown † | Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
288 | All | up to 17 Years (Child) | NCT00334672 | CDR0000481605 CCLG-LCH-2006-02 EU-20619 UKCCSG-HLH-2004 EUDRACT-2005-002187-28 |
March 2006 | November 2010 | June 8, 2006 | September 17, 2013 |
|
||||
17 | NCT02472054 | Recruiting | Treatment of Familiar Lymphohistiocytosis |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
30 | All | up to 17 Years (Child) | NCT02472054 | P120109 2014-005585-30 |
C-HLH | June 29, 2015 | October 2019 | April 2020 | June 15, 2015 | February 15, 2019 |
|
||
18 | NCT02862054 | Unknown † | Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
30 | All | 14 Years to 60 Years (Child, Adult) | NCT02862054 | Splenectomy-HLH | January 2015 | December 2017 | August 10, 2016 | August 10, 2016 |
|
||||
19 | NCT02385110 | Recruiting | Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT02385110 | 2014-0989 NCI-2015-00526 |
September 23, 2015 | September 2019 | September 2020 | March 11, 2015 | March 5, 2018 |
|
|||
20 | NCT01125319 | Completed | Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
120 | All | 18 Years and older (Adult, Older Adult) | NCT01125319 | 2007/35 2007-A01109-44 |
March 2010 | March 2014 | October 2014 | May 18, 2010 | July 1, 2015 |
|
|||
21 | NCT03510650 | Recruiting | Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU) |
|
Observational |
|
Other |
|
|
100 | All | 18 Years to 100 Years (Adult, Older Adult) | NCT03510650 | HEMICU | September 11, 2018 | July 30, 2020 | December 31, 2020 | April 27, 2018 | September 13, 2018 |
|
|||||
22 | NCT02854943 | Completed | The Prognostic and Diagnostic Value of Ferritin in Critically Ill Patients With Special Focus on Underlying Hemophagocytic Lymphohistiocytosis |
|
Observational |
|
Other |
|
|
258 | All | 18 Years and older (Adult, Older Adult) | NCT02854943 | HLH | January 2000 | June 2016 | June 2016 | August 4, 2016 | August 4, 2016 | ||||||
23 | NCT03827343 | Active, not recruiting New |
Retrospective Study of Immunotherapy Related Toxicities in Children and Adults With Cancer |
|
Observational |
|
NIH |
|
|
500 | All | up to 99 Years (Child, Adult, Older Adult) | NCT03827343 | 999919044 19-C-N044 |
January 23, 2019 | December 31, 2020 | December 31, 2020 | February 1, 2019 | February 8, 2019 |
|
|||||
24 | NCT03311854 | Recruiting | A Study to Investigate the Safety and Efficacy of an Anti-IFN-gamma mAb in Children With Systemic Juvenile Idiopathic Arthritis (sJIA) Developing Macrophage Activation Syndrome/ Secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH) |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
10 | All | up to 18 Years (Child, Adult) | NCT03311854 | NI-0501-06 | March 2, 2018 | May 2021 | May 2021 | October 17, 2017 | January 15, 2019 |
|
|||
25 | NCT02113917 | Unknown † | Children and Adult Hemophagocytic Syndrome (HLHa) |
|
|
Observational |
|
Other |
|
|
204 | All | 2 Years and older (Child, Adult, Older Adult) | NCT02113917 | NI10015 AOM 10219 |
HLH-genes | January 2010 | January 2016 | December 2016 | April 15, 2014 | August 26, 2016 |
|
|||
26 | NCT01494103 | Active, not recruiting | Administration of Donor T Cells With the Caspase-9 Suicide Gene |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
15 | All | Child, Adult, Older Adult | NCT01494103 | H-28256-DOTTI DOTTI |
DOTTI | November 2011 | May 2029 | May 2029 | December 16, 2011 | October 12, 2018 |
|
||
27 | NCT00006056 | Unknown † | Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders |
|
|
Interventional |
Not Applicable |
|
Other |
|
40 | All | up to 55 Years (Child, Adult) | NCT00006056 | 199/15106 UMN-MT-1997-08 UMN-MT-9708 |
March 2000 | July 6, 2000 | June 24, 2005 |
|
||||||
28 | NCT00368355 | Recruiting | T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
87 | All | up to 55 Years (Child, Adult) | NCT00368355 | H-8701-MOHEL | MOHEL | April 2000 | April 2019 | April 2020 | August 24, 2006 | August 10, 2018 |
|
||
29 | NCT00006054 | Terminated | Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies |
|
|
Interventional |
Not Applicable |
|
Other |
|
All | up to 35 Years (Child, Adult) | NCT00006054 | 199/15104 UMN-MT-1995-26 UMN-MT-9526 |
March 2000 | December 2002 | December 2002 | July 6, 2000 | October 15, 2009 |
|
|||||
30 | NCT02231710 | Active, not recruiting | Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
1 | All | 4 Months to 55 Years (Child, Adult) | NCT02231710 | BP-003 | February 2015 | July 16, 2015 | July 2030 | September 4, 2014 | January 29, 2019 |
|
|||
31 | NCT01998633 | Completed Has Results |
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) |
|
|
Interventional |
Phase 2 |
|
Other / NIH |
|
|
47 | All | 4 Months to 45 Years (Child, Adult) | NCT01998633 | BMTCTN1204 2U10HL069294-11 5U24CA076518 |
RICHI | December 2013 | September 23, 2016 | December 2016 | December 2, 2013 | June 1, 2018 | June 1, 2018 |
|
|
32 | NCT01966367 | Recruiting | CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation |
|
|
Interventional |
Early Phase 1 |
|
Other |
|
|
25 | All | up to 40 Years (Child, Adult) | NCT01966367 | AAAL0156 | March 2013 | December 2019 | December 2019 | October 21, 2013 | July 17, 2017 |
|
|||
33 | NCT01793168 | Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford |
|
Observational |
|
Other |
|
|
20000 | All | Child, Adult, Older Adult | NCT01793168 | 03-10-014 Hypersomnia Foundation National Ataxia Foundation 4p- Support Group CdLS Foundation Hyperacusis Research Limited Kabuki Syndrome Network Kawasaki Disease Foundation Klippel-Feil Syndrome Freedom Leiomyosarcoma Direct Research MSS Support Group ML4 Foundation Stickler Involved People IWSA Soft Bones PWN4PWN aHUS Klippel-Feil Syndrome Alliance American MEN Support Kleine-Levin Syndrome All Things Kabuki WSS Foundation BIVA ABDA PROS Foundation (HLH) Alagille Syndrome Association Cure VCP Disease, Inc. Lowe Syndrome Association Pitt Hopkins Cure Batten Disease Hypnic Jerk/Sleep Myoclonus |
CoRDS | July 2010 | December 2100 | December 2100 | February 15, 2013 | September 25, 2018 |
|
||||
34 | NCT00176865 | Completed Has Results |
Stem Cell Transplant for Immunologic or Histiocytic Disorders |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
19 | All | up to 35 Years (Child, Adult) | NCT00176865 | MT2002-12 0207M29448 |
August 2002 | August 2012 | August 2014 | September 15, 2005 | December 28, 2017 | April 14, 2017 |
|
||
35 | NCT00176826 | Terminated Has Results |
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
22 | All | up to 55 Years (Child, Adult) | NCT00176826 | UMN-MT2000-21 0010M66781 |
September 2000 | August 2012 | August 2015 | September 15, 2005 | January 23, 2018 | April 28, 2014 |
|
||
36 | NCT03546101 | Recruiting | Early Detection of Epstein-Barr Virus Related Disease. |
|
Observational |
|
Other |
|
|
600 | All | Child, Adult, Older Adult | NCT03546101 | EBV-KMA 1-16-02-685-16 |
March 1, 2018 | September 1, 2019 | March 1, 2022 | June 5, 2018 | June 5, 2018 |
|
|||||
37 | NCT03513328 | Recruiting | Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
40 | All | 6 Months to 38 Years (Child, Adult) | NCT03513328 | IRB201800798 PEDS024 OCR17838 |
June 15, 2018 | June 2021 | June 2022 | May 1, 2018 | January 16, 2019 |
|
|||
38 | NCT01652092 | Recruiting | Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
30 | All | up to 50 Years (Child, Adult) | NCT01652092 | 2012OC055 MT2012-10C |
September 4, 2012 | December 2019 | December 2021 | July 27, 2012 | January 15, 2019 |
|
|||
39 | NCT01917708 | Active, not recruiting | BMT Abatacept for Non-Malignant Diseases |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
10 | All | up to 21 Years (Child, Adult) | NCT01917708 | IRB00069836 | January 2014 | September 29, 2019 | September 29, 2019 | August 7, 2013 | November 6, 2018 |
|
|||
40 | NCT01821781 | Recruiting | Immune Disorder HSCT Protocol |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
20 | All | up to 21 Years (Child, Adult) | NCT01821781 | 201301135 | March 2013 | March 2019 | March 2021 | April 1, 2013 | November 21, 2017 |
|
† Study has passed its completion date and status has not been verified in more than two years.